# Regeneron Pharmaceuticals quarterly revenue

entity: /record/regeneron-pharmaceuticals.md  
predicate: quarterly_revenue  
page: /record/regeneron-pharmaceuticals/quarterly_revenue  
as_of: 2026-11-09  
cite: AsOf. "Regeneron Pharmaceuticals quarterly revenue: 5,115,800,000 United States dollar", as of 2026-09-30. Claim clm_15BDC7B1496E, https://asof.is/claim/clm_15BDC7B1496E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.  

As of November 9, 2026, Regeneron Pharmaceuticals's quarterly revenue on the AsOf record is $5.12 billion, dated September 30, 2026, from a primary source (sec.gov).

53 claims on Regeneron Pharmaceuticals's quarterly revenue, 1 open and 52 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted.

## Current quarterly revenue

What the record asserts on 2026-11-09.

- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 5,115,800,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_15BDC7B1496E](/claim/clm_15BDC7B1496E.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm

## Every dated value

One claim per line, oldest first. Superseded claims stay visible.

- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 90,032,000 United States dollar | valid 2009-06-30 to 2009-09-30 | conf 0.95 | superseded | superseded_by [clm_180A6BFB73AB](/claim/clm_180A6BFB73AB.md) | [clm_8F23955A5DC1](/claim/clm_8F23955A5DC1.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 117,455,000 United States dollar | valid 2009-09-30 to 2010-03-31 | conf 0.95 | superseded | superseded_by [clm_C140F465B911](/claim/clm_C140F465B911.md) | [clm_180A6BFB73AB](/claim/clm_180A6BFB73AB.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 103,534,000 United States dollar | valid 2010-03-31 to 2010-06-30 | conf 0.95 | superseded | superseded_by [clm_627655F53872](/claim/clm_627655F53872.md) | [clm_C140F465B911](/claim/clm_C140F465B911.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 115,886,000 United States dollar | valid 2010-06-30 to 2010-09-30 | conf 0.95 | superseded | superseded_by [clm_E85633B203A9](/claim/clm_E85633B203A9.md) | [clm_627655F53872](/claim/clm_627655F53872.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000120677410001689/0001206774-10-001689-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 105,979,000 United States dollar | valid 2010-09-30 to 2011-03-31 | conf 0.95 | superseded | superseded_by [clm_6475C30104FE](/claim/clm_6475C30104FE.md) | [clm_E85633B203A9](/claim/clm_E85633B203A9.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000120677410002228/0001206774-10-002228-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 112,204,000 United States dollar | valid 2011-03-31 to 2011-06-30 | conf 0.95 | superseded | superseded_by [clm_A35410AC229A](/claim/clm_A35410AC229A.md) | [clm_6475C30104FE](/claim/clm_6475C30104FE.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000120677411001105/0001206774-11-001105-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 107,810,000 United States dollar | valid 2011-06-30 to 2011-09-30 | conf 0.95 | superseded | superseded_by [clm_EC0E16DDB2D8](/claim/clm_EC0E16DDB2D8.md) | [clm_A35410AC229A](/claim/clm_A35410AC229A.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000120677411001639/0001206774-11-001639-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 102,833,000 United States dollar | valid 2011-09-30 to 2012-03-31 | conf 0.95 | superseded | superseded_by [clm_C5D81A308356](/claim/clm_C5D81A308356.md) | [clm_EC0E16DDB2D8](/claim/clm_EC0E16DDB2D8.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000120677411002300/0001206774-11-002300-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 231,789,000 United States dollar | valid 2012-03-31 to 2012-06-30 | conf 0.95 | superseded | superseded_by [clm_F838E1612E57](/claim/clm_F838E1612E57.md) | [clm_C5D81A308356](/claim/clm_C5D81A308356.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000120677412001689/0001206774-12-001689-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 304,399,000 United States dollar | valid 2012-06-30 to 2012-09-30 | conf 0.95 | superseded | superseded_by [clm_82AF3B3F2E9E](/claim/clm_82AF3B3F2E9E.md) | [clm_F838E1612E57](/claim/clm_F838E1612E57.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000120677412003062/0001206774-12-003062-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 427,687,000 United States dollar | valid 2012-09-30 to 2013-03-31 | conf 0.95 | superseded | superseded_by [clm_3E5F56BC8504](/claim/clm_3E5F56BC8504.md) | [clm_82AF3B3F2E9E](/claim/clm_82AF3B3F2E9E.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217612000004/0001532176-12-000004-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 439,664,000 United States dollar | valid 2013-03-31 to 2013-06-30 | conf 0.95 | superseded | superseded_by [clm_176F45465AD1](/claim/clm_176F45465AD1.md) | [clm_3E5F56BC8504](/claim/clm_3E5F56BC8504.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217613000008/0001532176-13-000008-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 457,642,000 United States dollar | valid 2013-06-30 to 2013-09-30 | conf 0.95 | superseded | superseded_by [clm_FFE707425BE2](/claim/clm_FFE707425BE2.md) | [clm_176F45465AD1](/claim/clm_176F45465AD1.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217613000022/0001532176-13-000022-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 597,027,000 United States dollar | valid 2013-09-30 to 2014-03-31 | conf 0.95 | superseded | superseded_by [clm_6885E2367C01](/claim/clm_6885E2367C01.md) | [clm_FFE707425BE2](/claim/clm_FFE707425BE2.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217613000030/0001532176-13-000030-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 625,740,000 United States dollar | valid 2014-03-31 to 2014-06-30 | conf 0.95 | superseded | superseded_by [clm_3B9F3E529762](/claim/clm_3B9F3E529762.md) | [clm_6885E2367C01](/claim/clm_6885E2367C01.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217614000022/0001532176-14-000022-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 665,700,000 United States dollar | valid 2014-06-30 to 2014-09-30 | conf 0.95 | superseded | superseded_by [clm_D15D4A6E6B04](/claim/clm_D15D4A6E6B04.md) | [clm_3B9F3E529762](/claim/clm_3B9F3E529762.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217614000035/0001532176-14-000035-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 725,788,000 United States dollar | valid 2014-09-30 to 2015-03-31 | conf 0.95 | superseded | superseded_by [clm_34333BB2CA3F](/claim/clm_34333BB2CA3F.md) | [clm_D15D4A6E6B04](/claim/clm_D15D4A6E6B04.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217614000046/0001532176-14-000046-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 869,612,000 United States dollar | valid 2015-03-31 to 2015-06-30 | conf 0.95 | superseded | superseded_by [clm_50CADC50AD04](/claim/clm_50CADC50AD04.md) | [clm_34333BB2CA3F](/claim/clm_34333BB2CA3F.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217615000020/0001532176-15-000020-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 998,617,000 United States dollar | valid 2015-06-30 to 2015-09-30 | conf 0.95 | superseded | superseded_by [clm_004FA2206A58](/claim/clm_004FA2206A58.md) | [clm_50CADC50AD04](/claim/clm_50CADC50AD04.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217615000029/0001532176-15-000029-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,137,422,000 United States dollar | valid 2015-09-30 to 2016-03-31 | conf 0.95 | superseded | superseded_by [clm_A146DEFD4AD2](/claim/clm_A146DEFD4AD2.md) | [clm_004FA2206A58](/claim/clm_004FA2206A58.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217615000037/0001532176-15-000037-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,200,849,000 United States dollar | valid 2016-03-31 to 2016-06-30 | conf 0.95 | superseded | superseded_by [clm_6B4AC1C07D2A](/claim/clm_6B4AC1C07D2A.md) | [clm_A146DEFD4AD2](/claim/clm_A146DEFD4AD2.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217616000055/0001532176-16-000055-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,212,629,000 United States dollar | valid 2016-06-30 to 2016-09-30 | conf 0.95 | superseded | superseded_by [clm_C7626FBBC9B4](/claim/clm_C7626FBBC9B4.md) | [clm_6B4AC1C07D2A](/claim/clm_6B4AC1C07D2A.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217616000067/0001532176-16-000067-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,220,122,000 United States dollar | valid 2016-09-30 to 2017-03-31 | conf 0.95 | superseded | superseded_by [clm_5AF2197029A2](/claim/clm_5AF2197029A2.md) | [clm_C7626FBBC9B4](/claim/clm_C7626FBBC9B4.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217616000082/0001532176-16-000082-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,318,991,000 United States dollar | valid 2017-03-31 to 2017-06-30 | conf 0.95 | superseded | superseded_by [clm_E83335CDCC26](/claim/clm_E83335CDCC26.md) | [clm_5AF2197029A2](/claim/clm_5AF2197029A2.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217617000017/0001532176-17-000017-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,470,116,000 United States dollar | valid 2017-06-30 to 2017-09-30 | conf 0.95 | superseded | superseded_by [clm_13C3FB7E9C67](/claim/clm_13C3FB7E9C67.md) | [clm_E83335CDCC26](/claim/clm_E83335CDCC26.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217617000027/0001532176-17-000027-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,500,673,000 United States dollar | valid 2017-09-30 to 2018-03-31 | conf 0.95 | superseded | superseded_by [clm_7E235362DFEC](/claim/clm_7E235362DFEC.md) | [clm_13C3FB7E9C67](/claim/clm_13C3FB7E9C67.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217617000034/0001532176-17-000034-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,511,485,000 United States dollar | valid 2018-03-31 to 2018-06-30 | conf 0.95 | superseded | superseded_by [clm_31D8E26EE368](/claim/clm_31D8E26EE368.md) | [clm_7E235362DFEC](/claim/clm_7E235362DFEC.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217618000020/0001532176-18-000020-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,608,022,000 United States dollar | valid 2018-06-30 to 2018-09-30 | conf 0.95 | superseded | superseded_by [clm_747F97C3BEDC](/claim/clm_747F97C3BEDC.md) | [clm_31D8E26EE368](/claim/clm_31D8E26EE368.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217618000028/0001532176-18-000028-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,663,496,000 United States dollar | valid 2018-09-30 to 2019-03-31 | conf 0.95 | superseded | superseded_by [clm_47864C915D20](/claim/clm_47864C915D20.md) | [clm_747F97C3BEDC](/claim/clm_747F97C3BEDC.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217618000036/0001532176-18-000036-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,711,800,000 United States dollar | valid 2019-03-31 to 2019-06-30 | conf 0.95 | superseded | superseded_by [clm_D84F29A094C8](/claim/clm_D84F29A094C8.md) | [clm_47864C915D20](/claim/clm_47864C915D20.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217619000017/0001532176-19-000017-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,933,700,000 United States dollar | valid 2019-06-30 to 2019-09-30 | conf 0.95 | superseded | superseded_by [clm_F3847C54AA19](/claim/clm_F3847C54AA19.md) | [clm_D84F29A094C8](/claim/clm_D84F29A094C8.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217619000026/0001532176-19-000026-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 2,048,400,000 United States dollar | valid 2019-09-30 to 2020-03-31 | conf 0.95 | superseded | superseded_by [clm_0BEF5E393370](/claim/clm_0BEF5E393370.md) | [clm_F3847C54AA19](/claim/clm_F3847C54AA19.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000153217619000034/0001532176-19-000034-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,828,200,000 United States dollar | valid 2020-03-31 to 2020-06-30 | conf 0.95 | superseded | superseded_by [clm_B16B9D90B428](/claim/clm_B16B9D90B428.md) | [clm_0BEF5E393370](/claim/clm_0BEF5E393370.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422020000011/0001804220-20-000011-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 1,952,000,000 United States dollar | valid 2020-06-30 to 2020-09-30 | conf 0.95 | superseded | superseded_by [clm_E888336416D4](/claim/clm_E888336416D4.md) | [clm_B16B9D90B428](/claim/clm_B16B9D90B428.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422020000022/0001804220-20-000022-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 2,294,000,000 United States dollar | valid 2020-09-30 to 2021-03-31 | conf 0.95 | superseded | superseded_by [clm_9488B81B5C8C](/claim/clm_9488B81B5C8C.md) | [clm_E888336416D4](/claim/clm_E888336416D4.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422020000030/0001804220-20-000030-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 2,528,700,000 United States dollar | valid 2021-03-31 to 2021-06-30 | conf 0.95 | superseded | superseded_by [clm_CBD2A7149F84](/claim/clm_CBD2A7149F84.md) | [clm_9488B81B5C8C](/claim/clm_9488B81B5C8C.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422021000017/0001804220-21-000017-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 5,138,500,000 United States dollar | valid 2021-06-30 to 2021-09-30 | conf 0.95 | superseded | superseded_by [clm_FC7E3BF6DC06](/claim/clm_FC7E3BF6DC06.md) | [clm_CBD2A7149F84](/claim/clm_CBD2A7149F84.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422021000025/0001804220-21-000025-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 3,452,800,000 United States dollar | valid 2021-09-30 to 2022-03-31 | conf 0.95 | superseded | superseded_by [clm_DA35C89878EA](/claim/clm_DA35C89878EA.md) | [clm_FC7E3BF6DC06](/claim/clm_FC7E3BF6DC06.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422021000033/0001804220-21-000033-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 2,965,100,000 United States dollar | valid 2022-03-31 to 2022-06-30 | conf 0.95 | superseded | superseded_by [clm_704A9CC6C45D](/claim/clm_704A9CC6C45D.md) | [clm_DA35C89878EA](/claim/clm_DA35C89878EA.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422022000015/0001804220-22-000015-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 2,857,200,000 United States dollar | valid 2022-06-30 to 2022-09-30 | conf 0.95 | superseded | superseded_by [clm_41EB8CF3FDDA](/claim/clm_41EB8CF3FDDA.md) | [clm_704A9CC6C45D](/claim/clm_704A9CC6C45D.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422022000023/0001804220-22-000023-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 2,936,200,000 United States dollar | valid 2022-09-30 to 2023-03-31 | conf 0.95 | superseded | superseded_by [clm_179FAEBC31F3](/claim/clm_179FAEBC31F3.md) | [clm_41EB8CF3FDDA](/claim/clm_41EB8CF3FDDA.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422022000031/0001804220-22-000031-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 3,162,100,000 United States dollar | valid 2023-03-31 to 2023-06-30 | conf 0.95 | superseded | superseded_by [clm_03FC6245728F](/claim/clm_03FC6245728F.md) | [clm_179FAEBC31F3](/claim/clm_179FAEBC31F3.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422023000016/0001804220-23-000016-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 3,158,100,000 United States dollar | valid 2023-06-30 to 2023-09-30 | conf 0.95 | superseded | superseded_by [clm_D14890ED012F](/claim/clm_D14890ED012F.md) | [clm_03FC6245728F](/claim/clm_03FC6245728F.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422023000023/0001804220-23-000023-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 3,362,700,000 United States dollar | valid 2023-09-30 to 2024-03-31 | conf 0.95 | superseded | superseded_by [clm_A39660FD9A27](/claim/clm_A39660FD9A27.md) | [clm_D14890ED012F](/claim/clm_D14890ED012F.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422023000031/0001804220-23-000031-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 3,145,000,000 United States dollar | valid 2024-03-31 to 2024-06-30 | conf 0.95 | superseded | superseded_by [clm_3891C0E928C4](/claim/clm_3891C0E928C4.md) | [clm_A39660FD9A27](/claim/clm_A39660FD9A27.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422024000017/0001804220-24-000017-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 3,547,100,000 United States dollar | valid 2024-06-30 to 2024-09-30 | conf 0.95 | superseded | superseded_by [clm_A6AD04E866B3](/claim/clm_A6AD04E866B3.md) | [clm_3891C0E928C4](/claim/clm_3891C0E928C4.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422024000028/0001804220-24-000028-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 3,720,700,000 United States dollar | valid 2024-09-30 to 2025-03-31 | conf 0.95 | superseded | superseded_by [clm_04C1A63A27E9](/claim/clm_04C1A63A27E9.md) | [clm_A6AD04E866B3](/claim/clm_A6AD04E866B3.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422024000040/0001804220-24-000040-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 3,028,700,000 United States dollar | valid 2025-03-31 to 2025-06-30 | conf 0.95 | superseded | superseded_by [clm_43E679905BB9](/claim/clm_43E679905BB9.md) | [clm_04C1A63A27E9](/claim/clm_04C1A63A27E9.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/0001804220-25-000022-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 3,675,600,000 United States dollar | valid 2025-06-30 to 2025-09-30 | conf 0.95 | superseded | superseded_by [clm_471EC2DBAE0B](/claim/clm_471EC2DBAE0B.md) | [clm_43E679905BB9](/claim/clm_43E679905BB9.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/0000872589-25-000019-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 3,754,300,000 United States dollar | valid 2025-09-30 to 2026-03-31 | conf 0.95 | superseded | superseded_by [clm_89291214D4AA](/claim/clm_89291214D4AA.md) | [clm_471EC2DBAE0B](/claim/clm_471EC2DBAE0B.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 3,605,400,000 United States dollar | valid 2026-03-31 to 2026-06-30 | conf 0.95 | superseded | superseded_by [clm_11098E7F99BC](/claim/clm_11098E7F99BC.md) | [clm_89291214D4AA](/claim/clm_89291214D4AA.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/0000872589-26-000016-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 4,290,700,000 United States dollar | valid 2026-06-30 to 2026-09-30 | conf 0.95 | superseded | superseded_by [clm_15BDC7B1496E](/claim/clm_15BDC7B1496E.md) | [clm_11098E7F99BC](/claim/clm_11098E7F99BC.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/0000872589-26-000025-index.htm
- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_revenue | 5,115,800,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_15BDC7B1496E](/claim/clm_15BDC7B1496E.md)
  sources: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm

## What replaced what

- $90.03 million (2009-06-30 to 2009-09-30, [clm_8F23955A5DC1](/claim/clm_8F23955A5DC1.md)) was replaced by $117.46 million from 2009-09-30 ([clm_180A6BFB73AB](/claim/clm_180A6BFB73AB.md))
- $117.46 million (2009-09-30 to 2010-03-31, [clm_180A6BFB73AB](/claim/clm_180A6BFB73AB.md)) was replaced by $103.53 million from 2010-03-31 ([clm_C140F465B911](/claim/clm_C140F465B911.md))
- $103.53 million (2010-03-31 to 2010-06-30, [clm_C140F465B911](/claim/clm_C140F465B911.md)) was replaced by $115.89 million from 2010-06-30 ([clm_627655F53872](/claim/clm_627655F53872.md))
- $115.89 million (2010-06-30 to 2010-09-30, [clm_627655F53872](/claim/clm_627655F53872.md)) was replaced by $105.98 million from 2010-09-30 ([clm_E85633B203A9](/claim/clm_E85633B203A9.md))
- $105.98 million (2010-09-30 to 2011-03-31, [clm_E85633B203A9](/claim/clm_E85633B203A9.md)) was replaced by $112.2 million from 2011-03-31 ([clm_6475C30104FE](/claim/clm_6475C30104FE.md))
- $112.2 million (2011-03-31 to 2011-06-30, [clm_6475C30104FE](/claim/clm_6475C30104FE.md)) was replaced by $107.81 million from 2011-06-30 ([clm_A35410AC229A](/claim/clm_A35410AC229A.md))
- $107.81 million (2011-06-30 to 2011-09-30, [clm_A35410AC229A](/claim/clm_A35410AC229A.md)) was replaced by $102.83 million from 2011-09-30 ([clm_EC0E16DDB2D8](/claim/clm_EC0E16DDB2D8.md))
- $102.83 million (2011-09-30 to 2012-03-31, [clm_EC0E16DDB2D8](/claim/clm_EC0E16DDB2D8.md)) was replaced by $231.79 million from 2012-03-31 ([clm_C5D81A308356](/claim/clm_C5D81A308356.md))
- $231.79 million (2012-03-31 to 2012-06-30, [clm_C5D81A308356](/claim/clm_C5D81A308356.md)) was replaced by $304.4 million from 2012-06-30 ([clm_F838E1612E57](/claim/clm_F838E1612E57.md))
- $304.4 million (2012-06-30 to 2012-09-30, [clm_F838E1612E57](/claim/clm_F838E1612E57.md)) was replaced by $427.69 million from 2012-09-30 ([clm_82AF3B3F2E9E](/claim/clm_82AF3B3F2E9E.md))
- $427.69 million (2012-09-30 to 2013-03-31, [clm_82AF3B3F2E9E](/claim/clm_82AF3B3F2E9E.md)) was replaced by $439.66 million from 2013-03-31 ([clm_3E5F56BC8504](/claim/clm_3E5F56BC8504.md))
- $439.66 million (2013-03-31 to 2013-06-30, [clm_3E5F56BC8504](/claim/clm_3E5F56BC8504.md)) was replaced by $457.64 million from 2013-06-30 ([clm_176F45465AD1](/claim/clm_176F45465AD1.md))
- $457.64 million (2013-06-30 to 2013-09-30, [clm_176F45465AD1](/claim/clm_176F45465AD1.md)) was replaced by $597.03 million from 2013-09-30 ([clm_FFE707425BE2](/claim/clm_FFE707425BE2.md))
- $597.03 million (2013-09-30 to 2014-03-31, [clm_FFE707425BE2](/claim/clm_FFE707425BE2.md)) was replaced by $625.74 million from 2014-03-31 ([clm_6885E2367C01](/claim/clm_6885E2367C01.md))
- $625.74 million (2014-03-31 to 2014-06-30, [clm_6885E2367C01](/claim/clm_6885E2367C01.md)) was replaced by $665.7 million from 2014-06-30 ([clm_3B9F3E529762](/claim/clm_3B9F3E529762.md))
- $665.7 million (2014-06-30 to 2014-09-30, [clm_3B9F3E529762](/claim/clm_3B9F3E529762.md)) was replaced by $725.79 million from 2014-09-30 ([clm_D15D4A6E6B04](/claim/clm_D15D4A6E6B04.md))
- $725.79 million (2014-09-30 to 2015-03-31, [clm_D15D4A6E6B04](/claim/clm_D15D4A6E6B04.md)) was replaced by $869.61 million from 2015-03-31 ([clm_34333BB2CA3F](/claim/clm_34333BB2CA3F.md))
- $869.61 million (2015-03-31 to 2015-06-30, [clm_34333BB2CA3F](/claim/clm_34333BB2CA3F.md)) was replaced by $998.62 million from 2015-06-30 ([clm_50CADC50AD04](/claim/clm_50CADC50AD04.md))
- $998.62 million (2015-06-30 to 2015-09-30, [clm_50CADC50AD04](/claim/clm_50CADC50AD04.md)) was replaced by $1.14 billion from 2015-09-30 ([clm_004FA2206A58](/claim/clm_004FA2206A58.md))
- $1.14 billion (2015-09-30 to 2016-03-31, [clm_004FA2206A58](/claim/clm_004FA2206A58.md)) was replaced by $1.2 billion from 2016-03-31 ([clm_A146DEFD4AD2](/claim/clm_A146DEFD4AD2.md))
- $1.2 billion (2016-03-31 to 2016-06-30, [clm_A146DEFD4AD2](/claim/clm_A146DEFD4AD2.md)) was replaced by $1.21 billion from 2016-06-30 ([clm_6B4AC1C07D2A](/claim/clm_6B4AC1C07D2A.md))
- $1.21 billion (2016-06-30 to 2016-09-30, [clm_6B4AC1C07D2A](/claim/clm_6B4AC1C07D2A.md)) was replaced by $1.22 billion from 2016-09-30 ([clm_C7626FBBC9B4](/claim/clm_C7626FBBC9B4.md))
- $1.22 billion (2016-09-30 to 2017-03-31, [clm_C7626FBBC9B4](/claim/clm_C7626FBBC9B4.md)) was replaced by $1.32 billion from 2017-03-31 ([clm_5AF2197029A2](/claim/clm_5AF2197029A2.md))
- $1.32 billion (2017-03-31 to 2017-06-30, [clm_5AF2197029A2](/claim/clm_5AF2197029A2.md)) was replaced by $1.47 billion from 2017-06-30 ([clm_E83335CDCC26](/claim/clm_E83335CDCC26.md))
- $1.47 billion (2017-06-30 to 2017-09-30, [clm_E83335CDCC26](/claim/clm_E83335CDCC26.md)) was replaced by $1.5 billion from 2017-09-30 ([clm_13C3FB7E9C67](/claim/clm_13C3FB7E9C67.md))
- $1.5 billion (2017-09-30 to 2018-03-31, [clm_13C3FB7E9C67](/claim/clm_13C3FB7E9C67.md)) was replaced by $1.51 billion from 2018-03-31 ([clm_7E235362DFEC](/claim/clm_7E235362DFEC.md))
- $1.51 billion (2018-03-31 to 2018-06-30, [clm_7E235362DFEC](/claim/clm_7E235362DFEC.md)) was replaced by $1.61 billion from 2018-06-30 ([clm_31D8E26EE368](/claim/clm_31D8E26EE368.md))
- $1.61 billion (2018-06-30 to 2018-09-30, [clm_31D8E26EE368](/claim/clm_31D8E26EE368.md)) was replaced by $1.66 billion from 2018-09-30 ([clm_747F97C3BEDC](/claim/clm_747F97C3BEDC.md))
- $1.66 billion (2018-09-30 to 2019-03-31, [clm_747F97C3BEDC](/claim/clm_747F97C3BEDC.md)) was replaced by $1.71 billion from 2019-03-31 ([clm_47864C915D20](/claim/clm_47864C915D20.md))
- $1.71 billion (2019-03-31 to 2019-06-30, [clm_47864C915D20](/claim/clm_47864C915D20.md)) was replaced by $1.93 billion from 2019-06-30 ([clm_D84F29A094C8](/claim/clm_D84F29A094C8.md))
- $1.93 billion (2019-06-30 to 2019-09-30, [clm_D84F29A094C8](/claim/clm_D84F29A094C8.md)) was replaced by $2.05 billion from 2019-09-30 ([clm_F3847C54AA19](/claim/clm_F3847C54AA19.md))
- $2.05 billion (2019-09-30 to 2020-03-31, [clm_F3847C54AA19](/claim/clm_F3847C54AA19.md)) was replaced by $1.83 billion from 2020-03-31 ([clm_0BEF5E393370](/claim/clm_0BEF5E393370.md))
- $1.83 billion (2020-03-31 to 2020-06-30, [clm_0BEF5E393370](/claim/clm_0BEF5E393370.md)) was replaced by $1.95 billion from 2020-06-30 ([clm_B16B9D90B428](/claim/clm_B16B9D90B428.md))
- $1.95 billion (2020-06-30 to 2020-09-30, [clm_B16B9D90B428](/claim/clm_B16B9D90B428.md)) was replaced by $2.29 billion from 2020-09-30 ([clm_E888336416D4](/claim/clm_E888336416D4.md))
- $2.29 billion (2020-09-30 to 2021-03-31, [clm_E888336416D4](/claim/clm_E888336416D4.md)) was replaced by $2.53 billion from 2021-03-31 ([clm_9488B81B5C8C](/claim/clm_9488B81B5C8C.md))
- $2.53 billion (2021-03-31 to 2021-06-30, [clm_9488B81B5C8C](/claim/clm_9488B81B5C8C.md)) was replaced by $5.14 billion from 2021-06-30 ([clm_CBD2A7149F84](/claim/clm_CBD2A7149F84.md))
- $5.14 billion (2021-06-30 to 2021-09-30, [clm_CBD2A7149F84](/claim/clm_CBD2A7149F84.md)) was replaced by $3.45 billion from 2021-09-30 ([clm_FC7E3BF6DC06](/claim/clm_FC7E3BF6DC06.md))
- $3.45 billion (2021-09-30 to 2022-03-31, [clm_FC7E3BF6DC06](/claim/clm_FC7E3BF6DC06.md)) was replaced by $2.97 billion from 2022-03-31 ([clm_DA35C89878EA](/claim/clm_DA35C89878EA.md))
- $2.97 billion (2022-03-31 to 2022-06-30, [clm_DA35C89878EA](/claim/clm_DA35C89878EA.md)) was replaced by $2.86 billion from 2022-06-30 ([clm_704A9CC6C45D](/claim/clm_704A9CC6C45D.md))
- $2.86 billion (2022-06-30 to 2022-09-30, [clm_704A9CC6C45D](/claim/clm_704A9CC6C45D.md)) was replaced by $2.94 billion from 2022-09-30 ([clm_41EB8CF3FDDA](/claim/clm_41EB8CF3FDDA.md))
- $2.94 billion (2022-09-30 to 2023-03-31, [clm_41EB8CF3FDDA](/claim/clm_41EB8CF3FDDA.md)) was replaced by $3.16 billion from 2023-03-31 ([clm_179FAEBC31F3](/claim/clm_179FAEBC31F3.md))
- $3.16 billion (2023-03-31 to 2023-06-30, [clm_179FAEBC31F3](/claim/clm_179FAEBC31F3.md)) was replaced by $3.16 billion from 2023-06-30 ([clm_03FC6245728F](/claim/clm_03FC6245728F.md))
- $3.16 billion (2023-06-30 to 2023-09-30, [clm_03FC6245728F](/claim/clm_03FC6245728F.md)) was replaced by $3.36 billion from 2023-09-30 ([clm_D14890ED012F](/claim/clm_D14890ED012F.md))
- $3.36 billion (2023-09-30 to 2024-03-31, [clm_D14890ED012F](/claim/clm_D14890ED012F.md)) was replaced by $3.15 billion from 2024-03-31 ([clm_A39660FD9A27](/claim/clm_A39660FD9A27.md))
- $3.15 billion (2024-03-31 to 2024-06-30, [clm_A39660FD9A27](/claim/clm_A39660FD9A27.md)) was replaced by $3.55 billion from 2024-06-30 ([clm_3891C0E928C4](/claim/clm_3891C0E928C4.md))
- $3.55 billion (2024-06-30 to 2024-09-30, [clm_3891C0E928C4](/claim/clm_3891C0E928C4.md)) was replaced by $3.72 billion from 2024-09-30 ([clm_A6AD04E866B3](/claim/clm_A6AD04E866B3.md))
- $3.72 billion (2024-09-30 to 2025-03-31, [clm_A6AD04E866B3](/claim/clm_A6AD04E866B3.md)) was replaced by $3.03 billion from 2025-03-31 ([clm_04C1A63A27E9](/claim/clm_04C1A63A27E9.md))
- $3.03 billion (2025-03-31 to 2025-06-30, [clm_04C1A63A27E9](/claim/clm_04C1A63A27E9.md)) was replaced by $3.68 billion from 2025-06-30 ([clm_43E679905BB9](/claim/clm_43E679905BB9.md))
- $3.68 billion (2025-06-30 to 2025-09-30, [clm_43E679905BB9](/claim/clm_43E679905BB9.md)) was replaced by $3.75 billion from 2025-09-30 ([clm_471EC2DBAE0B](/claim/clm_471EC2DBAE0B.md))
- $3.75 billion (2025-09-30 to 2026-03-31, [clm_471EC2DBAE0B](/claim/clm_471EC2DBAE0B.md)) was replaced by $3.61 billion from 2026-03-31 ([clm_89291214D4AA](/claim/clm_89291214D4AA.md))
- $3.61 billion (2026-03-31 to 2026-06-30, [clm_89291214D4AA](/claim/clm_89291214D4AA.md)) was replaced by $4.29 billion from 2026-06-30 ([clm_11098E7F99BC](/claim/clm_11098E7F99BC.md))
- $4.29 billion (2026-06-30 to 2026-09-30, [clm_11098E7F99BC](/claim/clm_11098E7F99BC.md)) was replaced by $5.12 billion from 2026-09-30 ([clm_15BDC7B1496E](/claim/clm_15BDC7B1496E.md))

## Questions this record answers

### What is Regeneron Pharmaceuticals's current quarterly revenue?

$5.12 billion, dated September 30, 2026, from a primary source (sec.gov). The record asserts this claim as of November 9, 2026 (status valid, confidence 0.95).

### When did Regeneron Pharmaceuticals's quarterly revenue last change?

The latest value on the record is $5.12 billion, dated September 30, 2026; before it the record holds $4.29 billion, dated June 30, 2026 and closed on September 30, 2026.

### What was Regeneron Pharmaceuticals's quarterly revenue before $5.12 billion?

$4.29 billion, valid from June 30, 2026 to September 30, 2026 (status superseded), from a primary source (sec.gov).


## Read on

- This page: /record/regeneron-pharmaceuticals/quarterly_revenue (markdown: /record/regeneron-pharmaceuticals/quarterly_revenue.md)
- Entity twin: /record/regeneron-pharmaceuticals.md · timeline: /timelines/regeneron-pharmaceuticals.md
- Every company's quarterly revenue: /facts/quarterly_revenue.md

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.